's Bulletin Board Post New Topic  New Poll  Post A Reply
my profile login | register | search | faq | forum home

  next oldest topic   next newest topic
»'s Bulletin Board » Pink Sheet Stocks » Protokinetix UPgraded to OTCQB..OFF the Pinks!

 - UBBFriend: Email this page to someone!    
Author Topic: Protokinetix UPgraded to OTCQB..OFF the Pinks!

Rate Member
Icon 6 posted      Profile for jackbequick     Send New Private Message       Edit/Delete Post   Reply With Quote 
**PKTX.. ProtoKinetix Upgrades to OTCQB... OFF of Pinks..!

ST. MARYS, W.Va., June 8, 2015 /PRNewswire/ -- ProtoKinetix, Incorporated (OTCQB: PKTX) (the "Company" or "ProtoKinetix") ( is pleased to announce that ProtoKinetix began trading today on the OTCQB(R) Venture Marketplace under the symbol "PKTX." The Company was formerly trading on the OTC Pink(R) marketplace under the same symbol.
U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the Company at:

"After considerable effort and significant investment in our public disclosure, we are proud to be trading on the OTCQB marketplace. This upgrade should broaden our shareholder base, improve liquidity and increase the visibility for our achievements going forward," said Clarence E. Smith, President and Chief Executive Officer of ProtoKinetix.

The OTCQB Venture Marketplace offers transparent trading in entrepreneurial and development stage U.S. and international companies. To be eligible, companies must be current in their financial reporting and must undergo an annual verification and management certification process. Companies must also meet a minimum one penny bid test and may not be in bankruptcy.

About ProtoKinetix

ProtoKinetix, Inc. (OTCQB: PKTX) is a molecular biotechnology company that has developed and patented a family of hyper stable, potent glycopeptides (AAGP(TM)) that enhance the therapeutic results and reduce the cost of stem cell medicine. Due to the anti-inflammatory effect of AAGP(TM) molecules, the Company is currently targeting the direct treatment of diseases that have a major inflammatory component.

The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Some information included in this press release contains statements that are forward-looking. Such forward-looking information involves significant risks and uncertainties that could affect anticipated results in the future and, accordingly, these results may differ materially from those expressed in any forward-looking statements made by or on behalf of the Company. For a description of additional risks and uncertainties, please refer to the Company's filings with the Securities and Exchange Commission.

Clarence E. Smith -- President and CEO [Big Grin]

The check is in the mail...

Posts: 153 | From: Florida | Registered: Dec 2009  |  IP: Logged | Report this post to a Moderator

Quick Reply

HTML is not enabled.
UBB Code™ is enabled.
UBB Code™ Images not permitted.
Instant Graemlins

Post New Topic  New Poll  Post A Reply Close Topic   Feature Topic   Move Topic   Delete Topic next oldest topic   next newest topic
 - Printer-friendly view of this topic
Hop To:

Contact Us | Message Board Home

© 1997 - 2018 All rights reserved.

Powered by Infopop Corporation
UBB.classic™ 6.7.2